PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2013102
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2013102
Choroideremia Market, By Treatment Type, By Route of Administration, By Patient Demographics, By Disease Stage, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
Choroideremia Market size was valued at US$ 9,785.95 Million in 2025, expanding at a CAGR of 4.87% from 2026 to 2033.
Choroideremia is a rare inherited eye disease that mainly affects males and slowly causes vision loss. It starts with difficulty seeing in the dark and gradually leads to loss of side vision and eventually central vision, sometimes resulting in blindness. It mainly affects males. According to government data from the U.S. National Institutes of Health, it affects about 1 in 50,000 to 100,000 people and contributes to a portion of blindness cases. The choroideremia market is the business around making and selling treatments for this rare eye disease, especially newer options like gene therapy. Even though very few people have it, the market is still expanding because companies are investing more in research, new treatment methods are being developed, and there is a clear need for treatments that can actually slow down or stop vision loss over time.
Choroideremia Market- Market Dynamics
Increasing Emphasis on Gene Therapy Development
A key factor driving the choroideremia market is the increasing development of gene therapy, backed by government support and regulatory incentives. The National Institutes of Health promotes gene therapy programs for rare diseases through funding and initiatives, as these conditions often have limited treatment options. Since choroideremia is caused by a single gene mutation, it is well suited for gene replacement approaches, and government-supported studies have already pushed these therapies into clinical trials with visible patient benefits. Companies like Biogen Inc., Spark Therapeutics, and REGENXBIO Inc. are actively working on such treatments. In addition, the U.S. Food and Drug Administration offers orphan drug and rare disease designations, helping companies move faster, which directly increases research activity and market growth.
Choroideremia Market- Segmentation Analysis:
The Global Choroideremia Market is segmented on the basis of Treatment Type, Route of Administration, Patient Demographics, Disease Stage, End User, and Region.
The market is split into six segments according to treatment type: Gene Therapy, Surgical Intervention, Pharmacological Treatment, Symptomatic Treatment, Cell Therapy, and Drug Therapy. Gene therapy is the most important part of this market because it directly fixes the main cause of the disease, the damaged CHM gene, while other options, like drugs or surgery, only manage symptoms and cannot stop vision loss. This disease is very rare, affecting roughly 1 in 50,000 to 100,000 people, which is why governments classify it under rare diseases and support development through orphan drug programs and research funding. Gene therapy stands out because it uses viral vectors (like AAV) to deliver a working gene into retinal cells, and clinical trials have already shown maintained or improved vision in some patients. Because it offers a one-time treatment approach, targets the root problem, and shows real clinical results, most funding, trials, and regulatory attention are focused on gene therapy, making it the most widely adopted segment.
The market is structured into four segments in terms of Route of Administration: Subretinal Injection, Intravitreal Injection, Oral Route, and Intravenous Route. The subretinal injection is anticipated to play a central role in the choroideremia market because it delivers gene therapy directly to the damaged retinal cells where the disease occurs. Government-supported clinical research shows that gene therapies for choroideremia are primarily administered through subretinal delivery, as seen in trials using AAV-based treatments that directly target the retinal pigment epithelium and photoreceptors. Scientific studies also confirm that subretinal injection provides more precise and effective delivery compared to other routes, ensuring higher drug concentration at the target site. This approach is widely used by companies such as Spark Therapeutics and REGENXBIO Inc., which focus on AAV-based therapies requiring direct retinal delivery. Key features of this segment include targeted gene transfer, improved treatment effectiveness, and suitability for one-time therapy, which makes it the most widely adopted route despite being more invasive than alternatives like intravitreal injection.
Choroideremia Market- Geographical Insights
North America is forecasted to register meaningful growth of the choroideremia market due to its strong research base and consistent government support for rare disease therapies. The National Institutes of Health funds multiple gene therapy programs for inherited retinal diseases, supporting both early-stage and clinical research, while the U.S. Food and Drug Administration provides orphan drug designations that help speed up treatment development. Government-backed studies in the U.S. have already advanced gene therapy for choroideremia into human trials with measurable vision improvements, supported by companies such as Spark Therapeutics and REGENXBIO Inc. Europe represents the next significant region, supported by active clinical research and public healthcare involvement, where government-backed trials in the United Kingdom, including funding from the UK Department of Health, have contributed to early human studies of subretinal gene therapy, along with structured rare disease policies that support ongoing research and patient access.
Canada Choroideremia Market- Country Insights
Canada represents an important country in the choroideremia market due to steady government-supported research and a clear healthcare focus on rare eye diseases. According to data supported by organizations like Fighting Blindness Canada, around 21,000 Canadians are living with inherited retinal diseases, including choroideremia, showing a defined patient base that requires long-term care and treatment. In addition, government-linked clinical studies in Canada highlight that over 68% of patients with these conditions are legally blind, indicating a serious healthcare burden and the need for effective therapies. The country also has strong academic and clinical involvement, with institutions such as the University of Alberta contributing to genetic research and the diagnosis of choroideremia. Companies and research groups working with gene-based approaches are supported through public healthcare systems and collaborations with global biotech firms. Overall, Canada's structured healthcare system, ongoing research efforts, and clearly identified patient population support continued development and adoption of new treatments in a stable and organized manner.
Choroideremia Market- Competitive Landscape:
The competitive landscape of the choroideremia market is shaped by a group of biotechnology and pharmaceutical companies focusing on gene-based treatments, as there are limited approved options and ongoing clinical development. Key players include Biogen Inc., Spark Therapeutics, REGENXBIO Inc., MeiraGTx Holdings plc, and 4D Molecular Therapeutics, all working on AAV-based gene therapies targeting the underlying genetic cause. Government-supported clinical data show that multiple gene therapy trials for choroideremia have already progressed to Phase I, II, and III stages across the U.S., UK, and other regions, indicating steady development activity. In addition, public research funding from institutions such as the National Institute for Health and Care Research in the UK and similar government bodies supports clinical studies and infrastructure for these trials. The market remains research-driven, with companies focusing on clinical trial advancement, regulatory approvals, and long-term treatment outcomes, as gene therapy continues to be the primary area of development.
Recent Developments:
In October 2025, DelveInsight and other industry pipeline insights highlighted expanding clinical research and multi-modal approaches (gene therapy, gene editing, RNA-based therapies, optogenetics) advancing through preclinical and clinical stages for choroideremia, signaling broadening therapeutic research activity. This trend reflects a gradual shift toward more diverse treatment strategies, with multiple technologies being explored to address the disease from different angles, indicating steady progress in development efforts and a wider scope for future therapeutic options.
In June 2025, the Choroideremia Research Foundation awarded six new global research grants to accelerate vision science and treatment innovation in choroideremia, funding projects including CRISPR-based gene editing and long-term gene therapy follow-up studies. This reflects continued financial and scientific support for advanced research approaches, with a clear focus on improving long-term treatment outcomes and expanding the scope of therapeutic development for the condition.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CHOROIDEREMIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- MeiraGTx Limited (U.K.)
- REGENXBIO (U.S.)
- GenSight Biologics (France)
- Editas Medicine (U.S.)
- Spark Therapeutics (U.S.)
- Sangamo Therapeutics (U.S.)
- CRISPR Therapeutics AG (Switzerland)
- Nanoscope Therapeutics, Inc. (U.S.)
- 4D Molecular Therapeutics (U.S.)
- ProQR Therapeutics N.V. (Netherlands)
- Horama SA (France)
- Homology Medicines, Inc. (U.S.)
- Beacon Therapeutics (U.S.)
- Eyevensys (Switzerland)
- Visgenx (U.S.)
- Atsena Therapeutics Inc. (U.S.)
- Coave Therapeutics (U.S.)
- Neurophth Therapeutics (China)
- Johnson & Johnson Services, Inc. (U.S.)
- Ocugen, Inc. (U.S.)
GLOBAL CHOROIDEREMIA MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033
- Gene Therapy
- Surgical Intervention
- Pharmacological Treatment
- Symptomatic Treatment
- Cell Therapy
- Drug Therapy
GLOBAL CHOROIDEREMIA MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Subretinal Injection
- Intravitreal Injection
- Oral Route
- Intravenous Route
GLOBAL CHOROIDEREMIA MARKET, BY PATIENT DEMOGRAPHICS- MARKET ANALYSIS, 2020 - 2033
- Pediatric Patients
- Adult Patients
- Geriatric Patients
GLOBAL CHOROIDEREMIA MARKET, BY DISEASE STAGE- MARKET ANALYSIS, 2020 - 2033
- Early Stage
- Mid Stage
- Late Stage
GLOBAL CHOROIDEREMIA MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Hospitals
- Specialty Ophthalmology Clinics
- Ambulatory Surgical Centers
- Research & Academic Institutes
- Homecare Settings
GLOBAL CHOROIDEREMIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Choroideremia Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Choroideremia Market Snippet by Treatment Type
- 2.1.2. Choroideremia Market Snippet by Route of Administration
- 2.1.3. Choroideremia Market Snippet by Patient Demographics
- 2.1.4. Choroideremia Market Snippet by Disease Stage
- 2.1.5. Choroideremia Market Snippet by End User
- 2.1.6. Choroideremia Market Snippet by Country
- 2.1.7. Choroideremia Market Snippet by Region
- 2.2. Competitive Insights
3. Choroideremia Key Market Trends
- 3.1. Choroideremia Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Choroideremia Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Choroideremia Market Opportunities
- 3.4. Choroideremia Market Future Trends
4. Choroideremia Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Choroideremia Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Choroideremia Market Landscape
- 6.1. Choroideremia Market Share Analysis, 2025
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Choroideremia Market - By Treatment Type
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
- 7.1.2. Gene Therapy
- 7.1.3. Surgical Intervention
- 7.1.4. Pharmacological Treatment
- 7.1.5. Symptomatic Treatment
- 7.1.6. Cell Therapy
- 7.1.7. Drug Therapy
8. Choroideremia Market - By Route of Administration
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
- 8.1.2. Subretinal Injection
- 8.1.3. Intravitreal Injection
- 8.1.4. Oral Route
- 8.1.5. Intravenous Route
9. Choroideremia Market - By Patient Demographics
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Patient Demographics, 2025 & 2033 (%)
- 9.1.2. Pediatric Patients
- 9.1.3. Adult Patients
- 9.1.4. Geriatric Patients
10. Choroideremia Market - By Disease Stage
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
- 10.1.2. Early Stage
- 10.1.3. Mid Stage
- 10.1.4. Late Stage
11. Choroideremia Market - By End User
- 11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
- 11.1.2. Hospitals
- 11.1.3. Specialty Ophthalmology Clinics
- 11.1.4. Ambulatory Surgical Centers
- 11.1.5. Research & Academic Institutes
- 11.1.6. Homecare Settings
12. Choroideremia Market- By Geography
- 12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
- 12.2. North America
- 12.2.1. Overview
- 12.2.2. Choroideremia Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.2.9. U.S.
- 12.2.9.1. Overview
- 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.2.9.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.2.9.5. U.S. Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.2.9.6. U.S. Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.2.9.7. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.2.10. Canada
- 12.2.10.1. Overview
- 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.2.10.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.2.10.5. Canada Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.2.10.6. Canada Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.2.10.7. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3. Europe
- 12.3.1. Overview
- 12.3.2. Choroideremia Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.9. Germany
- 12.3.9.1. Overview
- 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.9.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.9.5. Germany Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.9.6. Germany Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.9.7. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.10. UK
- 12.3.10.1. Overview
- 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.10.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.10.5. UK Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.10.6. UK Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.10.7. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.11. France
- 12.3.11.1. Overview
- 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.11.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.11.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.11.5. France Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.11.6. France Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.11.7. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.12. Italy
- 12.3.12.1. Overview
- 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.12.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.12.5. Italy Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.12.6. Italy Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.12.7. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.13. Spain
- 12.3.13.1. Overview
- 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.13.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.13.5. Spain Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.13.6. Spain Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.13.7. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.14. The Netherlands
- 12.3.14.1. Overview
- 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.14.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.14.5. The Netherlands Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.15. Sweden
- 12.3.15.1. Overview
- 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.15.5. Sweden Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.15.6. Sweden Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.15.7. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.16. Russia
- 12.3.16.1. Overview
- 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.16.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.16.5. Russia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.16.6. Russia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.16.7. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.17. Poland
- 12.3.17.1. Overview
- 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.17.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.17.5. Poland Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.17.6. Poland Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.17.7. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.18. Rest of Europe
- 12.3.18.1. Overview
- 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.18.5. Rest of the Europe Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Choroideremia Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.9. China
- 12.4.9.1. Overview
- 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.4.9.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.9.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.9.5. China Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.9.6. China Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.9.7. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.10. India
- 12.4.10.1. Overview
- 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.4.10.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.10.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.10.5. India Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.10.6. India Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.10.7. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.11. Japan
- 12.4.11.1. Overview
- 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.11.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.11.5. Japan Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.11.6. Japan Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.11.7. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.12. South Korea
- 12.4.12.1. Overview
- 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.12.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.12.5. South Korea Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.12.6. South Korea Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.12.7. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.13. Australia
- 12.4.13.1. Overview
- 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.13.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.13.5. Australia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.13.6. Australia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.13.7. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.14. Indonesia
- 12.4.14.1. Overview
- 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.14.5. Indonesia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.14.6. Indonesia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.15. Thailand
- 12.4.15.1. Overview
- 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.15.5. Thailand Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.15.6. Thailand Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.15.7. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.16. Philippines
- 12.4.16.1. Overview
- 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.16.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.16.5. Philippines Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.16.6. Philippines Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.16.7. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.17. Rest of APAC
- 12.4.17.1. Overview
- 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.17.5. Rest of APAC Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Choroideremia Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.9. Brazil
- 12.5.9.1. Overview
- 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.5.9.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.9.5. Brazil Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.5.9.6. Brazil Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.5.9.7. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.10. Mexico
- 12.5.10.1. Overview
- 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.5.10.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.10.5. Mexico Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.5.10.6. Mexico Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.5.10.7. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.11. Argentina
- 12.5.11.1. Overview
- 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.5.11.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.11.5. Argentina Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.5.11.6. Argentina Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.5.11.7. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.12. Colombia
- 12.5.12.1. Overview
- 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.5.12.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.12.5. Colombia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.5.12.6. Colombia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.5.12.7. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.13. Rest of LATAM
- 12.5.13.1. Overview
- 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.5.13.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.13.5. Rest of LATAM Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Choroideremia Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.9. Saudi Arabia
- 12.6.9.1. Overview
- 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.6.9.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.9.5. Saudi Arabia Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.10. United Arab Emirates
- 12.6.10.1. Overview
- 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.6.10.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.10.5. United Arab Emirates Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.11. Israel
- 12.6.11.1. Overview
- 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.6.11.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.11.5. Israel Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.6.11.6. Israel Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.6.11.7. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.12. Turkey
- 12.6.12.1. Overview
- 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.6.12.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.12.5. Turkey Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.6.12.6. Turkey Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.6.12.7. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.13. Algeria
- 12.6.13.1. Overview
- 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.6.13.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.13.5. Algeria Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.6.13.6. Algeria Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.6.13.7. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.14. Egypt
- 12.6.14.1. Overview
- 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.6.14.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.14.5. Egypt Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.6.14.6. Egypt Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.6.14.7. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.15. Rest of MEA
- 12.6.15.1. Overview
- 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 12.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.15.5. Rest of MEA Market Size and Forecast, By Patient Demographics, 2020 - 2033 (US$ Million)
- 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Stage, 2020 - 2033 (US$ Million)
- 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
13. Key Vendor Analysis- Choroideremia Industry
- 13.1. Competitive Benchmarking
- 13.1.1. Competitive Dashboard
- 13.1.2. Competitive Positioning
- 13.2. Company Profiles
- 13.2.1. MeiraGTx Limited (U.K.)
- 13.2.2. REGENXBIO (U.S.)
- 13.2.3. GenSight Biologics (France)
- 13.2.4. Editas Medicine (U.S.)
- 13.2.5. Spark Therapeutics (U.S.)
- 13.2.6. Sangamo Therapeutics (U.S.)
- 13.2.7. CRISPR Therapeutics AG (Switzerland)
- 13.2.8. Nanoscope Therapeutics, Inc. (U.S.)
- 13.2.9. 4D Molecular Therapeutics (U.S.)
- 13.2.10. ProQR Therapeutics N.V. (Netherlands)
- 13.2.11. Horama SA (France)
- 13.2.12. Homology Medicines, Inc. (U.S.)
- 13.2.13. Beacon Therapeutics (U.S.)
- 13.2.14. Eyevensys (Switzerland)
- 13.2.15. Visgenx (U.S.)
- 13.2.16. Atsena Therapeutics Inc. (U.S.)
- 13.2.17. Coave Therapeutics (U.S.)
- 13.2.18. Neurophth Therapeutics (China)
- 13.2.19. Johnson & Johnson Services, Inc. (U.S.)
- 13.2.20. Ocugen, Inc. (U.S.)
14. 360 Degree Analyst View
15. Appendix
- 15.1. Research Methodology
- 15.2. References
- 15.3. Abbreviations
- 15.4. Disclaimer
- 15.5. Contact Us
